Anti-Diabetes Drugs - Brazil | Statista Market Forecast

The Anti-Diabetes Drugs market in Brazil is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is projected to reach US$1.55bn by 2024.
Furthermore, it is anticipated that the market will exhibit a compound annual growth rate (CAGR 2024-2029) of 7.62%, resulting in a market volume of US$2.24bn by 2029.
When compared globally, United States is expected to generate the highest revenue in the Anti-Diabetes Drugs market, with a projected revenue of US$37.84bn in 2024.
Brazil is experiencing a surge in demand for anti-diabetes drugs as the country grapples with a growing diabetes epidemic.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in Brazil has been experiencing steady growth in recent years.

Customer preferences: Brazil has a large population of people with diabetes, which has led to a high demand for anti-diabetes drugs. Patients in Brazil tend to prefer oral medications over injectables, which has driven the growth of the oral anti-diabetes drugs market in the country. Additionally, patients are increasingly looking for drugs that not only manage their blood sugar levels but also have fewer side effects.

Trends in the market: The Brazilian government has been taking steps to increase access to anti-diabetes drugs for its citizens. One such initiative is the "Farmacia Popular" program, which provides low-cost medications to the population. This program has helped to increase the availability of anti-diabetes drugs in the country and has contributed to the growth of the market.Another trend in the market is the increasing use of generic drugs. Generic drugs have been gaining popularity in Brazil due to their lower cost compared to branded drugs. This trend has led to increased competition in the market, which has driven down prices and made anti-diabetes drugs more affordable for patients.

Local special circumstances: Brazil has a large population of people with diabetes, which has led to a high demand for anti-diabetes drugs. Additionally, the country has a public healthcare system that provides free or low-cost healthcare to its citizens. This has helped to increase access to anti-diabetes drugs for patients who may not be able to afford them otherwise.

Underlying macroeconomic factors: Brazil's economy has been slowly recovering from a recession, which has led to increased spending on healthcare. This has helped to drive the growth of the anti-diabetes drugs market in the country. Additionally, Brazil has a large pharmaceutical industry, which has contributed to the availability of anti-diabetes drugs in the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.